Search research articles
Contact Us
Filters
Showing results (731-740 of 831) with videos related to
Page
of 84
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Breast Cancer Research and Treatment
|
November 15, 2011
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
Michaela J Higgins, Tatiana M Prowell, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2020
The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Cesar A Santa-Maria, Janelle W Coughlin, Dipali Sharma, et al.
Respiratory Research
|
January 17, 2025
Optimization of a micro-scale air-liquid-interface model of human proximal airway epithelium for moderate throughput drug screening for SARS-CoV-2
Chandani Sen, Tammy M Rickabaugh, Arjit Vijey Jeyachandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2021
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Roisin M Connolly, Jeffrey P Leal, Lilja Solnes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Lisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Archives of Pathology & Laboratory Medicine
|
January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
Kimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Page
of 84
Search research articles
Search
Showing results (731-740 of 831) with videos related to
Sort By:
Page
of 84
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Breast Cancer Research and Treatment
|
November 15, 2011
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer
Michaela J Higgins, Tatiana M Prowell, Amanda L Blackford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 7, 2019
A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
Ingrid A Mayer, Aleix Prat, Daniel Egle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 20, 2020
The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote Trial
Cesar A Santa-Maria, Janelle W Coughlin, Dipali Sharma, et al.
Respiratory Research
|
January 17, 2025
Optimization of a micro-scale air-liquid-interface model of human proximal airway epithelium for moderate throughput drug screening for SARS-CoV-2
Chandani Sen, Tammy M Rickabaugh, Arjit Vijey Jeyachandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2021
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Roisin M Connolly, Jeffrey P Leal, Lilja Solnes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 6, 2012
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
Lisa A Carey, Hope S Rugo, P Kelly Marcom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 9, 2013
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, et al.
Archives of Pathology & Laboratory Medicine
|
January 14, 2020
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
Kimberly H Allison, M Elizabeth H Hammond, Mitchell Dowsett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
Andres Forero-Torres, Katherine E Varley, Vandana G Abramson, et al.
Page
of 84